Studying How Certain Genes Affect the Success of Medications (Buprenorphine and Naloxone) for Opioid Addiction Treatment
Not Applicable
- Conditions
- Health Condition 1: F112- Opioid dependence
- Registration Number
- CTRI/2024/02/063348
- Lead Sponsor
- PGIMER, Chandigarh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age: 18-65 years, Either gender, Diagnosis of moderate or severe OUD as per DSM-V criteria or opioid dependence as per ICD-11, Providing written informed consent, Participants within a week of initiating buprenorphine naloxone (BNX) treatment.
Exclusion Criteria
Presence of cardiomyopathy, Patients with liver disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do OPRD1 and OPRM1 genetic polymorphisms influence Buprenorphine/Naloxone pharmacodynamics in opioid use disorder patients?
What is the comparative effectiveness of Buprenorphine/Naloxone versus standard-of-care treatments in OPRM1 variant opioid dependence patients?
Which OPRD1 and OPRM1 variants serve as predictive biomarkers for Buprenorphine/Naloxone response in F112 opioid dependence (PGIMER CTRI/2024/02/063348)?
How do OPRM1 and OPRD1 polymorphisms affect adverse event profiles and management strategies for Buprenorphine/Naloxone in opioid addiction treatment?
What alternative opioid receptor modulators or combination therapies target OPRD1/OPRM1 pathways for treating F112 opioid dependence?